Nothing said here yet.
to join the conversation.
| Maria Elvira Salazar | Sell | $8.0K | Thu, Sep 24 | Thu, Oct 1 |
| Kevin Hern | Sell | $8.0K | Tue, Aug 18 | Thu, Aug 27 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| Gilbert Cisneros | Buy | $8.0K | Fri, Jun 5 | Thu, Jul 2 |
| Maria Elvira Salazar | Sell | $32.5K | Tue, Jun 2 | Wed, Jul 1 |
| Maria Elvira Salazar | Buy | $8.0K | Tue, May 12 | Mon, Jun 1 |
| Maria Elvira Salazar | Buy | $83.0K | Mon, May 11 | Mon, Jun 1 |
Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not
Biogen shareholders woke up to a pullback. The stock closed at US$244.05, down 3.4% from the prior session, even though Q3 2026 revenue reached US$2.8b with double digit year on year growth and free cash flow hit US$600m.
Biogen (NASDAQ:BIIB) reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio.
Moby summary of Biogen Inc.'s Q3 2026 earnings call
Growth portfolio revenue jumped 49%, now 63% of core pharma sales.
Biogen crushed third-quarter expectations early Tuesday, helped by its suite of newer products and leading to a guidance boost.
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.
Biogen Inc. (NASDAQ:BIIB) reported third-quarter 2026 earnings and revenue above analyst expectations on Wednesday, supported by growth across its newer treatments and the first full-quarter contribution from products acquired through its purchase of Apellis…
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.